» Authors » Miyuki Shimoji

Miyuki Shimoji

Explore the profile of Miyuki Shimoji including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 15
Citations 184
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Koinuma K, Noto K, Morita T, Uekusa Y, Kikuchi H, Shimoji M, et al.
J Pharm Sci . 2024 Oct; 114(2):849-856. PMID: 39481475
Some citrus fruits are known to cause clinically significant drug interactions by inhibiting intestinal cytochrome P450 (CYP) enzymes. This in vitro study aimed to investigate the kinetics of the inhibition...
2.
Kojima M, Machida K, Cho S, Watanabe D, Seki H, Shimoji M, et al.
Xenobiotica . 2023 Aug; 53(5):357-365. PMID: 37584614
1. Temperature is considered to affect the activity of drug-metabolizing enzymes; however, no previous studies have compared temperature dependency among cytochrome P450 genetic variants. This study aimed to analyse warfarin...
3.
Sihombing A, Murata S, Shimoji M, Miyake T, Takebayashi K, Kodama H, et al.
Anticancer Res . 2023 May; 43(6):2491-2500. PMID: 37247920
Background/aim: The role of CD44 in gastric cancer-derived peritoneal metastasis is currently unknown. It was previously shown that viable, tumorigenic cancer cells are spilled into the peritoneal cavity during surgery,...
4.
Misaki S, Murata S, Shimoji M, Iwai T, Sihombing A, Aoki K, et al.
Jpn J Radiol . 2022 Jun; 40(12):1307-1315. PMID: 35763240
Purpose: Treatments for metastatic human epidermal growth factor receptor 2 (HER2)-positive tumors are improving but remain inadequate. We investigated activating antitumor immune response by combining radiation therapy with immune checkpoint...
5.
Takebayashi K, Murata S, Kodama H, Kaida S, Yamaguchi T, Ishikawa K, et al.
Eur J Surg Oncol . 2021 May; 48(1):177-182. PMID: 34034940
Background: Cancer cells in intraoperative peritoneal washings (PW) indicate increased peritoneal recurrence. Detection of CEA or CK20 genes indicates poor prognosis. We assessed long-term prognosis of patients with amplification of...
6.
Shimoji M, Figueroa R, Neve E, Maksel D, Imreh G, Morgenstern R, et al.
Biochim Biophys Acta Biomembr . 2016 Dec; 1859(2):238-244. PMID: 27913278
Microsomal glutathione transferase 1 (MGST1) is a membrane bound enzyme involved in the detoxification of reactive electrophiles and protection of membranes from oxidative stress. The enzyme displays an unusual and...
7.
Zhou X, Bi H, Wong J, Shimoji M, Wang Y, Yuan J, et al.
J Toxicol Environ Health A . 2011 Nov; 74(22-24):1493-503. PMID: 22043910
Prion diseases are a group of incurable transmissible neurodegenerative disorders. The key molecular event in the pathogenesis of prion diseases is the conversion of the cellular prion protein (PrP(C)) into...
8.
Zou R, Fujioka H, Guo J, Xiao X, Shimoji M, Kong C, et al.
Aging (Albany NY) . 2011 Oct; 3(10):968-84. PMID: 21990137
A distinct conformational transition from the α-helix-rich cellular prion protein (PrPC) into its β-sheet-rich pathological isoform (PrPSc) is the hallmark of prion diseases, a group of fatal transmissible encephalopathies that...
9.
Johansson K, Ito M, Schophuizen C, Mathew Thengumtharayil S, Heuser V, Zhang J, et al.
Mol Pharm . 2011 Aug; 8(5):1698-708. PMID: 21851097
Resistance against anticancer drugs remains a serious obstacle in cancer treatment. Here we used novel strategies to target microsomal glutathione transferase 1 (MGST1) and glutathione transferase pi (GSTP) that are...
10.
Zou W, Puoti G, Xiao X, Yuan J, Qing L, Cali I, et al.
Ann Neurol . 2010 Aug; 68(2):162-72. PMID: 20695009
Objective: The objective of the study is to report 2 new genotypic forms of protease-sensitive prionopathy (PSPr), a novel prion disease described in 2008, in 11 subjects all homozygous for...